

# ATT 3b: OD2A-LOCAL Annual Performance Report and Work Plan

Form Approved  
OMB NO: 0920-1283  
Exp. Date: 05/31/2026

Public reporting burden of this collection of information is estimated to average 12 hours per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/Information Collection Review Office, 1600 Clifton Road, NE, MS H21-8, Atlanta, GA 30333; Attn: PRA (0920-1283).

## WORK PLAN

### List of Population-Specific Questions for Prevention Strategies

**Please identify the priority populations for your prevention strategies.**

*(A priority population is a population that would benefit from an intervention in terms of reduced risk of overdose. For example, if an overdose prevention training for law enforcement officers is implemented, the officers would be the audience for the intervention, but the priority population might be the persons at risk for overdose in the community who would benefit from law enforcement helping to preventing overdose deaths and link persons at risk of overdose to treatment.) (select all that apply)*

- Race and ethnicity
- Sex
- Age group
- Persons involved in the criminal justice setting
- People experiencing homelessness
- Persons who recently experienced an overdose
- Urban populations
- Rural populations
- Other priority populations

**For each population identified:**

- Which data sources are you using to inform this choice of priority population? *(select all that apply)*
  - Hospital discharge data
  - Emergency department syndromic surveillance data
  - Electronic health record (EHR) data
  - EMS data
  - Biosurveillance data
  - PDMP data
  - Public safety data
  - Data from community partners
  - Evaluation data

- o Survey data
  - o Other data source (please specify):
- Why was this population chosen?
  - How will the interventions lead to improved health outcomes for disproportionately affected populations?
  - Please select all prevention strategies that will focus on this population. *(select all that apply)*
    - o Linkage to and Retention in Care
    - o Harm reduction
    - o Stigma reduction
    - o Clinician and Health Systems Best Practices
    - o Health IT Enhancements

**For each strategy selected**, how do the data, or evidence, show that the population can be impacted through this strategy (why was this strategy chosen for this population)?

## List of Partner Questions for Prevention Strategies

**Please identify the partners with whom you will work to conduct your prevention strategies.**

(Partners should include all internal and external partners such as subrecipients/contractors, community partners, public safety partners, health care system partners, and other partners you will work with to conduct prevention strategies. Partners can be grouped if they are part of one program, for example, you are funding multiple sub-awardees to complete similar work.)

- Please select the strategies in which the partner will be involved.
- For each strategy, specify the interventions in which the partner will be involved.

**Please answer the follow questions for each partner identified:**

- Describe how you will engage with this partner (for each strategy/intervention selected) and how this partnership will facilitate implementation efforts.
- Describe how you will share key data (e.g., morbidity, mortality, programmatic, evaluation) with this partner to facilitate the implementation of prevention interventions.
- By engaging this partner, how does both your work and their work improve overall efforts to prevent overdoses?

## Component A

### List of Questions for Strategy 1 (Prevention): Linkage to and Retention in Care

#### Data Source

- Please select data source types that will be used to inform this strategy. *(select all that apply)*
  - Hospital discharge data
  - Emergency department syndromic surveillance data
  - Electronic health record (EHR) data
  - EMS data
  - Biosurveillance data
  - PDMP data
  - Public safety data
  - Data from community partners
  - Evaluation data
  - Survey data
  - Other data source (please specify):
- Describe partners that would be involved with data interpretation (e.g., persons with lived experience, community partners), and describe how they will play a role in using these data to inform, prioritize, and make changes to program implementation.
- Describe how you plan on using these data to ensure that interventions within this strategy are feasible, evidence-based, and address high priority needs.

#### Implementation

*(Intervention level questions will need to be answered for each intervention selected.)*

- Please specify your linkage to and retention in care interventions.
  - Use navigators to support linkage to care (required)
  - Use navigators to link persons to community-based overdose prevention services (required)
  - Implement peer support programs
  - Provide training and support to peers working with persons at increased risk of overdose
  - Implement low-barrier, culturally-relevant and innovative connections throughout community services
  - Implement culturally-relevant public safety-led programs that facilitate rapid linkage to care (e.g., safe stations, post-overdose outreach, law enforcement-assisted diversion or deflection)
  - Implement universal screening and linkage to care protocols via multidisciplinary teams
  - Build bidirectional connections across clinical, social/behavioral service settings, and public safety
  - Enhance telehealth capabilities in local healthcare sites to broad access to care
  - Develop electronic resource hubs such as a comprehensive database of clinicians and facilities offering treatment
  - Other
- Please select the settings for this intervention.
  - Community
  - Healthcare
  - Public safety

- What is the intended audience for the intervention?
- Please describe the intervention, including what you are doing and how you are conducting the intervention and with whom.
- Do you plan to evaluate this intervention? (*Required interventions will need to be evaluated, but evaluating other interventions is optional*)
  - If yes, or required for evaluation, please identify the short-term outcomes you will evaluate for this intervention?
  - If yes, or required for evaluation, please identify the intermediate-term outcomes you will evaluate for this intervention?

## Intervention Steps

(These are the steps necessary to complete the intervention selected above. Steps include planning to conducting the intervention to dissemination of findings to evaluation. Recipients will be able to add several steps per intervention.)

- Please enter the name of step.
- Please provide a description of the step.
- What is the anticipated start date for this step?
- What is the anticipated date of completion for this step?

## List of Questions for Strategy 2 (Prevention): Harm Reduction

### Data Source

- Please select data source types that will be used to inform this strategy. (*select all that apply*)
  - Hospital discharge data
  - Emergency department syndromic surveillance data
  - Electronic health record (EHR) data
  - EMS data
  - Biosurveillance data
  - PDMP data
  - Public safety data
  - Data from community partners
  - Evaluation data
  - Survey data
  - Other data source (please specify):
- Describe partners would be involved with data interpretation (e.g., persons with lived experience, community partners), and describe how they will play a role in using these data to inform, prioritize, and make changes to program implementation.
- Describe how you plan on using these data to ensure that interventions within this strategy are feasible, evidence-based, and address high priority needs.

## Implementation

(Intervention level questions will need to be answered for each intervention selected.)

- Please specify your linkage to and retention in care interventions.
  - o Distribute naloxone to populations at highest risk of overdose or to populations with disparate rates of overdose (required)
  - o Partner with community-based overdose prevention programs to improve access to services for persons or groups disproportionately affected by or at increased risk of overdose
  - o Support co-design of community-based overdose prevention programs with communities disproportionately affected by or at increased risk of overdose
  - o Build and strengthen coalitions that support local community-based overdose prevention environments and access to life-saving strategies
  - o Develop a network to provide naloxone and fentanyl test strip distribution or other drug checking technology approved by CDC
  - o Implement focused education and communication campaigns tailored to various populations to share timely data on trends in local drug supply
  - o Inform and educate local decision makers on the science of community-based overdose prevention strategies by providing scientific evidence and locally-generated data
  - o Develop communications that quickly and efficiently communicate findings from drug checking surveillance or other local data sources
  - o Promote first responders facilitating access to community-based overdose prevention programs
  - o Develop and implement plans to respond to acute events, such as overdose spikes
  - o Provide naloxone and overdose prevention education to persons who are incarcerated or detained prior to or upon release
  - o Educate and train public safety personnel on evidence-based overdose prevention strategies, with a focus on persons who are overrepresented in the criminal justice continuum
  - o Partner with clinicians to ensure persons at high risk of an opioid overdose have access to naloxone, either via a prescription or direct provision.
  - o Provide access to overdose prevention services in health systems
  - o Ensure clinicians understand local community-based overdose prevention resources and understand how to help PWUD access services
  - o Equip clinicians with education on evidence-based overdose prevention practices to enhance counseling for PWUD.
  - o Other
  
- Please select the settings for this intervention.
  - o Community
  - o Healthcare
  - o Public safety
  
- What is the intended audience for the intervention?
- Please describe the intervention, including what you are doing and how you are conducting the intervention and with whom.
- Do you plan to evaluate this intervention? *(Required interventions will need to be evaluated, but evaluating other interventions is optional)*
  - o If yes, or required for evaluation, please identify the short-term outcomes you will evaluate for this intervention?

- o If yes, or required for evaluation, please identify the intermediate-term outcomes you will evaluate for this intervention?

## Intervention Steps

*(These are the steps necessary to complete the intervention selected above. Steps include planning to conducting the intervention to dissemination of findings to evaluation. Recipients will be able to add several steps per intervention.)*

- Please enter the name of step.
- Please provide a description of the step.
- What is the anticipated start date for this step?
- What is the anticipated date of completion for this step?

## List of Questions for Strategy 3 (Prevention): Stigma Reduction

### Data Source

- Please select data source types that will be used to inform this strategy. *(select all that apply)*
  - o Hospital discharge data
  - o Emergency department syndromic surveillance data
  - o Electronic health record (EHR) data
  - o EMS data
  - o Biosurveillance data
  - o PDMP data
  - o Public safety data
  - o Data from community partners
  - o Evaluation data
  - o Survey data
  - o Other data source (please specify):
- Describe partners would be involved with data interpretation (e.g., persons with lived experience, community partners), and describe how they will play a role in using these data to inform, prioritize, and make changes to program implementation.
- Describe how you plan on using these data to ensure that interventions within this strategy are feasible, evidence-based, and address high priority needs.

### Implementation

*(Intervention level questions will need to be answered for each intervention selected.)*

- Please specify your linkage to and retention in care interventions.
  - o Implement an anti-stigma program for the local health department and/or health system employees
  - o Build opportunities to connect local overdose prevention programs within the community to reduce stigmatizing attitudes towards these services
  - o Reduce stigma towards naloxone use while educating the public on naloxone access and use, in conjunction with educating about the availability of effective treatments for SUD
  - o Train on Good Samaritan Laws or other policies that affect PWUDs for any community member or organization to reduce stigma towards overdose prevention

- o Develop and adapt culturally relevant program training and implementation for public safety and criminal justice personnel including the promotion of referral to evidence-based SUD services for people with SUDs
  - o Implement anti-stigma focused training for first engagement with people with SUD for first responders and appropriate subsequent referral to health services
  - o Conduct training incorporating engagement with people with lived experience of SUDs to reduce stigma and humanize the lived experience of people living with SUDs among public safety officers
  - o Examine with public safety whether policies and protocols that relate to engagement with people with SUDs and their treatment are stigma-free and accessible for different populations
  - o Develop a roll call video for law enforcement that discusses risks and treatment for substance use disorder and the impact of stigmatizing language and behavior upon people with OUD
  - o Implement anti-stigma education for clinicians to address stigma about PWUD, community-based overdose prevention services, and recovery.
  - o Organize and integrate clinician and health system training on the role of stigma for the provision of pain management and SUD care, including how stigmatizing practices may reduce access to care and care delivery, and to implement anti-stigma didactic education
  - o Examine policies and protocols for treatment of people with pain and/or OUD to ensure that access to pain medication and treatment for SUDs is available across the healthcare system
  - o Other
- Please select the settings for this intervention.
    - o Community
    - o Healthcare
    - o Public safety
  - What is the intended audience for the intervention?
  - Please describe the intervention, including what you are doing and how you are conducting the intervention and with whom.
  - Do you plan to evaluate this intervention?
    - o If yes, please identify the short-term outcomes you will evaluate for this intervention?
    - o If yes, please identify the intermediate-term outcomes you will evaluate for this intervention?

## Intervention Steps

*(These are the steps necessary to complete the intervention selected above. Steps include planning to conducting the intervention to dissemination of findings to evaluation. Recipients will be able to add several steps per intervention.)*

- Please enter the name of step.
- Please provide a description of the step.
- What is the anticipated start date for this step?
- What is the anticipated date of completion for this step?

## List of Questions for Strategy 4 (Prevention): Clinician and Health Systems Best Practices

### Data Source

- Please select data source types that will be used to inform this strategy. *(select all that apply)*
  - o Hospital discharge data
  - o Emergency department syndromic surveillance data

- o Electronic health record (EHR) data
  - o EMS data
  - o Biosurveillance data
  - o PDMP data
  - o Public safety data
  - o Data from community partners
  - o Evaluation data
  - o Survey data
  - o Other data source (please specify):
- Describe partners would be involved with data interpretation (e.g., persons with lived experience, community partners), and describe how they will play a role in using these data to inform, prioritize, and make changes to program implementation.
  - Describe how you plan on using these data to ensure that interventions within this strategy are feasible, evidence-based, and address high priority needs.

## Implementation

*(Intervention level questions will need to be answered for each intervention selected.)*

- Please specify your linkage to and retention in care interventions.
  - o Advance clinician best practices for acute, subacute, and chronic pain treatment including opioid prescribing, as described in the CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022 (required)
  - o Identify and address differences in access to in pain management practices, SUD diagnosis and care.
  - o Build comfort and confidence among clinicians to support provision of pain care as well as MOUD
  - o Train, implement, and adopt trauma-informed practices into health system and clinical staff policies and standards
  - o Expand fundamental knowledge of screening and care for polysubstance use, OUD, and StUD, with special attention paid to raising awareness of specific community/local options for care
  - o Other
- What is the intended audience for the intervention?
- Please describe the intervention, including what you are doing and how you are conducting the intervention and with whom.
- Do you plan to evaluate this intervention? *(Required interventions will need to be evaluated, but evaluating other interventions is optional)*
  - o If yes, or required for evaluation, please identify the short-term outcomes you will evaluate for this intervention?
  - o If yes, or required for evaluation, please identify the intermediate-term outcomes you will evaluate for this intervention?

## Intervention Steps

*(These are the steps necessary to complete the intervention selected above. Steps include planning to conducting the intervention to dissemination of findings to evaluation. Recipients will be able to add several steps per intervention.)*

- Please enter the name of step.
- Please provide a description of the step.

- What is the anticipated start date for this step?
- What is the anticipated date of completion for this step?

## List of Strategy-level Questions for Strategy 5 (Prevention): Health IT Enhancements

### Data Source

- Please select data source types that will be used to inform this strategy. *(select all that apply)*
  - o Hospital discharge data
  - o Emergency department syndromic surveillance data
  - o Electronic health record (EHR) data
  - o EMS data
  - o Biosurveillance data
  - o PDMP data
  - o Public safety data
  - o Data from community partners
  - o Evaluation data
  - o Survey data
  - o Other data source (please specify):
- Describe partners would be involved with data interpretation (e.g., persons with lived experience, community partners), and describe how they will play a role in using these data to inform, prioritize, and make changes to program implementation.
- Describe how you plan on using these data to ensure that interventions within this strategy are feasible, evidence-based, and address high priority needs.

### Implementation

*(Intervention level questions will need to be answered for each intervention selected.)*

- Please specify your linkage to and retention in care interventions.
  - o Build formal frameworks and mechanisms to facilitate actionable and computable sharing of state-collected data for local implementation and integration into health system EHRs
  - o Support creation of electronic CDS tools and/or quality improvement measures to bring tailored data into EHRs in an actionable and computable format for clinicians thereby streamlining clinical workflow
  - o Other
- What is the intended audience for the intervention?
- Please describe the intervention, including what you are doing and how you are conducting the intervention and with whom.
- Do you plan to evaluate this intervention?
  - o If yes, please identify the short-term outcomes you will evaluate for this intervention?
  - o If yes, please identify the intermediate-term outcomes you will evaluate for this intervention?

## Intervention Steps

(These are the steps necessary to complete the intervention selected above. Steps include planning to conducting the intervention to dissemination of findings to evaluation. Recipients will be able to add several steps per intervention.)

- Please enter the name of step.
- Please provide a description of the step.
- What is the anticipated start date for this step?
- What is the anticipated date of completion for this step?

## List of Questions for Strategy 6 (Surveillance): Surveillance Infrastructure Building

Please describe each of your surveillance infrastructure building objectives. (*free-text response written as specific, measurable, achievable, realistic, and timebound [SMART] objectives*). Please describe no more than 10 objectives.

### For each surveillance infrastructure building objective identified:

- What are the expected outputs of this objective during the upcoming funding year?
- How are outputs of this objective anticipated to improve drug overdose surveillance?
- During the upcoming funding year, what is the expected time frame for achieving this objective (specifying the number of months)?
- Please describe the key partners involved in helping you engage in surveillance infrastructure building.

## Component B

## List of Questions for Component B (Surveillance): Drug Product and Paraphernalia Testing

### Implement Surveillance System

- Describe your efforts to identify all laboratory(ies) performing testing. For each laboratory identified, provide the following information:
  - Please provide the name(s) of the laboratory(ies) conducting testing.
  - Please describe the type of testing conducting by each laboratory conducting testing.
  - Identify an annual goal for the number of samples that will be tested in a free text field.
- Describe the types of samples that you plan to test during the upcoming funding year (*select all that apply*)
  - Drug product samples (e.g., pills, powders)
  - Syringes
  - Plastic bags containing drugs
  - Cooker
  - Cotton
  - Foil
  - Other drug paraphernalia
  - Other (provide text)

- Briefly describe the plan for obtaining drug products and/or drug paraphernalia samples tested. This should include descriptions of:
  - o How the samples are being obtained (e.g., ME/C, law enforcement)?
  - o The sampling plan (e.g., test all samples or test a random sample of specimens).
- Do you receive the additional ME/C funding under Component B?
  - o If YES, please describe planned enhancements to ME/C drug overdose death investigations and/or sharing of data between ME/C agencies and your local health department.

## **CDC Data Reporting and Workgroup Participation Requirements**

- List the people or job positions that will participate in the CDC workgroup for this component.

## **Disseminate Data**

- Describe plans for data dissemination, including proposed product descriptions and how they will be shared with key partners.

# **Component C**

## **List of Questions for Component C (Surveillance): Linkage to and Retention in Care Surveillance**

### **Implement Surveillance System**

- Identify the entry point(s) for which your jurisdiction plans to collect linkage to and retention in care surveillance indicators during the upcoming funding year (*select all that apply*)
  - o Emergency department
  - o Other hospital department
  - o Emergency medical services (EMS)
  - o Community partners
  - o Public safety partners
  - o Other (provide text)
- Describe the data sources that your jurisdiction plans to use to support linkage to and retention in care surveillance during the reporting period.
- Describe how your jurisdiction plans to obtain and maintain access to key data sources to support linkage to and retention in care surveillance during the reporting period, including anticipated challenges and plans to address them.
- Describe how your jurisdiction plans to establish and maintain data systems to support linkage to and retention in care surveillance during the reporting period, including anticipated challenges and plans to address them.
- Is your jurisdiction planning to collect individual-level data that are linked across indicators during the reporting period?
  - o If no, what are the barriers to collecting individual-level data and how do you plan to address them?

## ***CDC Data Reporting and Workgroup Participation Requirements***

- List the people or job positions that will participate in the CDC workgroup for this strategy.

## ***Disseminate Data***

- Describe plans for data dissemination, including descriptions of planned products and how they will be shared with key partners.

## Overall Budget Section

The following list of budget items should be submitted via the identified electronic mechanism provided by your OD2A support team. You may use the following list to prepare a complete and accurate budget response.

## Personnel Salary & Fringe

<b>Salary Total</b>	\$	<b>Fringe Total</b>	\$
<b>Salary: Component 1</b>	\$	<b>Fringe: Component 1</b>	\$
<b>Salary: Component 2</b>	\$	<b>Fringe: Component 2</b>	\$
<b>Salary: Component 3</b>	\$	<b>Fringe: Component 3</b>	\$
<b>Salary: Component 4</b>	\$	<b>Fringe: Component 4</b>	\$

Personnel Cost					
Name of Personnel	Position Title	Annual Salary/Wages	% Paid by this Grant	Months	Salary and Wages
					\$
	<b>Fringe</b>	<b>Fringe (%)</b>	<b>Fringe (\$) if not %</b>	<b>Fringe</b>	<b>Total Planned</b>
			\$	\$	\$
Justification					
Allocations					
Funding Category	% Allocated	\$ Allocated (Salary/Wages)	\$ Allocated to Fringe	Total Allocated	
<b>Component 1</b>		\$	\$	\$	
<b>Component 2</b>		\$	\$	\$	
<b>Component 3</b>		\$	\$	\$	
<b>Component 4</b>		\$	\$	\$	
*Note: Please duplicate this table for each OD2A personnel needed for budget reporting					

# Contracts

<b>Total for Contract</b>	\$	<b>Component 3</b>	\$
<b>Component 1</b>	\$	<b>Component 4</b>	\$
<b>Component 2</b>	\$	<b>Indirect Cost</b>	\$

Basic Information		
<b>Contractor Title</b>		
<b>Method of Selection</b>		
<b>Justification for Sole Source Selection</b>		
<b>Period of Performance</b>		
<b>Scope of Work (Describe the specific services/tasks to be performed by the contractor, how they relate to the accomplishment of program objectives, and the specific strategy(ies) they align with. Please be sure deliverables are clearly defined.)</b>		
<b>Method of Accountability</b>		
Allocations		
<b>Funding Category</b>	<b>% Allocated</b>	<b>\$ Allocated</b>
<b>Component 1</b>		\$
<b>Component 2</b>		\$
<b>Component 3</b>		\$
<b>Component 4</b>		\$
*Note: Please duplicate this table for each OD2A personnel needed for budget reporting		

Itemized Costs		Justification
<b>Salary and Wages</b>	\$	
<b>Fringe Benefits</b>	\$	
<b>Consultant Cost</b>	\$	
<b>Equipment</b>	\$	
<b>Supplies</b>	\$	
<b>Travel</b>	\$	
<b>Deliverable Cost</b>	\$	
<b>Other describe</b>	\$	

<b>Other Describe</b>		\$	
<b>Other describe</b>		\$	
<b>Subcontract Cost</b>		\$	
<b>Total Direct Costs</b>		\$	
<b>Indirect Costs</b>		\$	
<b>Total For Contract</b>		\$	
*Note: Please duplicate this table for each OD2A personnel needed for budget reporting			

## Consultants

<b>Total for Consultant</b>	\$	<b>Component 2</b>	\$
<b>Component 1</b>	\$	<b>Component 3</b>	\$
		<b>Component 4</b>	\$

Basic Information		
<b>Consultant Title</b>		
<b>Organizational Affiliation</b>		
<b>Nature of Services to Be Rendered</b>		
<b>Relevance of Service to the project</b>		
<b>Method of Accountability</b>		
Allocations		
<b>Funding Category</b>	<b>% Allocated</b>	<b>\$ Allocated</b>
<b>Component 1</b>		\$
<b>Component 2</b>		\$
<b>Component 3</b>		\$
<b>Component 4</b>		\$
*Note: Please duplicate this table for each OD2A personnel needed for budget reporting		

Itemized Costs		Justification
Number of Days of Consultation		
Expected Daily Rate of Compensation		
<b>BASE COMPENSATION SUBTOTAL</b>	\$	
Travel	\$	
Per Diem (total for all days consultation)	\$	
Supplies	\$	
<b>Deliverable Cost</b>	\$	
<b>Other describe</b>	\$	
<b>Other describe</b>	\$	
<b>Other describe</b>	\$	
<b>Other describe</b>	\$	
<b>Other describe</b>	\$	
<b>Expenses Subtotal</b>	\$	
<b>Total For Consultant</b>	\$	
*Note: Please duplicate this table for each OD2A personnel needed for budget reporting		

# Equipment

Equipment costs are for items with a <u>unit cost</u> over \$10,000.					Allocations									
Line #	Item Requested	Number Needed	Unit Cost	Total Amount Planned	% Allocated [Component 1]	% Allocated [Component 2]	% Allocated [Component 3]	% Allocated [Component 4]	\$ Allocated [Component 1]	\$ Allocated [Component 2]	\$ Allocated [Component 3]	\$ Allocated [Component 4]	Justification	
1				\$					\$	\$	\$	\$		
2				\$					\$	\$	\$	\$		
3				\$					\$	\$	\$	\$		
4				\$					\$	\$	\$	\$		
5				\$					\$	\$	\$	\$		

# Supplies

Line #	Item Requested	Type (if appropriate)	Number Needed	Unit Cost	Amount Planned	% Allocated [Component 1]	% Allocated [Component 2]	% Allocated [Component 3]	% Allocated [Component 4]	\$ Allocated [Component 1]	\$ Allocated [Component 2]	\$ Allocated [Component 3]	\$ Allocated [Component 4]	Justification
1					\$					\$	\$	\$	\$	
2					\$					\$	\$	\$	\$	
3					\$					\$	\$	\$	\$	

# Travel

	Description (include location and travel event)	# of People	Cost of Mileage or Airfare	Cost of Per Diem or Lodging	Cost of Ground Transport	Other Costs	Amount Planned	% Allocated [Component 1]	% Allocated [Component 2]	% Allocated [Component 3]	% Allocated [Component 4]	\$ Allocated [Component 1]	\$ Allocated [Component 2]	\$ Allocated [Component 3]	\$ Allocated [Component 4]	Justification (Please include names of persons traveling and reason for travel)
1							\$					\$	\$	\$	\$	
2							\$					\$	\$	\$	\$	
3							\$					\$	\$	\$	\$	
4							\$					\$	\$	\$	\$	

## Other

Line #	Item Requested	Number Needed	Unit Cost	Amount Planned	% Allocated [Component 1]	% Allocated [Component 2]	% Allocated [Component 3]	% Allocated [Component 4]	\$ Allocated [Component 1]	\$ Allocated [Component 2]	\$ Allocated [Component 3]	\$ Allocated [Component 4]	Justification
1				\$					\$	\$	\$	\$	
2				\$					\$	\$	\$	\$	
3				\$					\$	\$	\$	\$	
4				\$					\$	\$	\$	\$	

## Summary

Recipient	Budget Period Year

Object Class	Component 1	Component 2	Component 3	Component 4	Grand Total
Salary and Wages	\$	\$	\$	\$	\$
Fringe Benefits	\$	\$	\$	\$	\$
Contractual Costs	\$	\$	\$	\$	\$
Consultant Costs	\$	\$	\$	\$	\$
Equipment	\$	\$	\$	\$	\$
Supplies	\$	\$	\$	\$	\$
Travel	\$	\$	\$	\$	\$
Other	\$	\$	\$	\$	\$
<b>Direct Cost</b>	\$	\$	\$	\$	\$
<b>Indirect Costs</b>	\$	\$	\$	\$	\$
<b>TOTAL</b>	\$	\$	\$	\$	\$
<b>Target</b>	\$	\$	\$	\$	\$
<b>Balance</b>	\$	\$	\$	\$	\$

Indirect Cost Justification
Please remember to submit a copy of your <b>current approved</b> indirect cost rate agreement.

# ANNUAL PERFORMANCE REPORT

## List of Success Stories Questions: Prevention

**PREVENTION STRATEGIES:** Please answer the following question with consideration of all of your prevention strategies.

### SUCCESS STORIES

Success stories are particularly important tools that: Allow CDC to elevate the work of jurisdictions, foster connections and sharing of promising practices among jurisdictions, and inform areas/ideas where TA could be introduced/enhanced.

**Title (Let your readers know what to expect from the story)**

#### Challenge

- Describe the public health problem that you sought to address.
- List all the data sources that were used to identify the problem and the priority population.

#### Approach

- Describe the priority population.
- Describe how data were used to inform the intervention implemented.
- WHERE and WHEN did the intervention take place?
- HOW did the intervention address the Challenge?
- WHO was involved, including major partners?
- WHAT innovative approaches were used?

#### Results

- What happened as a result of the work you did?
- Why is that result important? (Describe the “so what?”)
- What are short-term, intermediate, or long-term outcomes that demonstrate how the intervention had an impact (e.g., how many people were reached, what practices/behaviors changed, how much money was saved, if any policies were changed or developed, how was the Challenge addressed)? Please refer back to your logic model and quantify your outcomes when possible.

## Component A

### List of Questions for Strategy 1 (Prevention): Linkage to and Retention in Care

#### Data To Action

- Describe all data analyzed to inform interventions for this strategy and any partner involvement with analysis, interpretation, and program refinement (provide examples of relevant analysis).
- How did implementation of interventions change as a result of the use of these data?
- What were the impacts or results from the implementation change?
- What additional data gaps, if any, did you identify?
- Provide examples of how you used/shared near real-time data (e.g., ODMAP, syndromic) to inform rapid community responses to spikes in drug overdoses or dangerous drug supplies.
- Describe your approach to using data and implementing interventions to address the needs of persons at high risk of overdose.

#### Intervention Progress

##### For each intervention:

- Describe your progress to date for this intervention, including progress engaging your priority populations. (Highlight any significant successes or challenges. Describe barriers and how you overcame them and any relevant facilitators.)
- Please list all relevant outputs and deliverables produced as a result of this intervention (select all that apply)
  - o Publications
  - o Presentations
  - o Abstracts
  - o Toolkits
  - o Dashboards/Data Viz
  - o Training Materials
  - o Other
- Please indicate whether you will continue with this intervention in the next year? (*whether this is continued or not should be reflected in the workplan for the coming year*)

#### Step-Level Progress

- Indicate your completion status for this step. (*Already Completed, On Schedule, Delayed, Discontinued*)
  - o Why was this step not completed (Only answer if completion status is not “Already Completed” or “On Schedule”).
  - o What are your plans for completion (Only answer if completion status is not “Already Completed” or “Discontinued”).

- o Anticipated completion date (Only answer if completion status is not “Already Completed” or “Discontinued”).
- o What are your plans to redirect funds budgeted for this step to another step or a different intervention? (Only answer completion status is “Discontinued”)

## Technical Assistance

- Would technical assistance be helpful in the implementation of your interventions within this strategy?
  - o If yes, what type of support may be needed?

## List of Questions for Strategy 2 (Prevention): Harm Reduction

### Data To Action

- Describe all data analyzed to inform interventions for this strategy and any partner involvement with analysis, interpretation, and program refinement (provide examples of relevant analysis).
- How did implementation of interventions change as a result of the use of these data?
- What were the impacts or results from the implementation change?
- What additional data gaps, if any, did you identify?
- Provide examples of how you used/shared near real-time data (e.g., ODMAP, syndromic) to inform rapid community responses to spikes in drug overdoses or dangerous drug supplies.
- Describe your approach to using data and implementing interventions to address the needs of persons at high risk of overdose.

### Intervention Progress

#### For each intervention:

- Describe your progress to date for this intervention, including progress engaging your priority populations. (Highlight any significant successes or challenges. Describe barriers and how you overcame them and any relevant facilitators.)
- Please list all relevant outputs and deliverables produced as a result of this intervention (select all that apply)
  - o Publications
  - o Presentations
  - o Abstracts
  - o Toolkits
  - o Dashboards/Data Viz
  - o Training Materials
  - o Other

- Please indicate whether you will continue with this intervention in the next year? *(whether this is continued or not should be reflected in the workplan for the coming year)*

## Step-Level Progress

- Indicate your completion status for this step. *(Already Completed, On Schedule, Delayed, Discontinued)*
  - o Why was this step not completed (Only answer if completion status is not “Already Completed” or “On Schedule”).
  - o What are your plans for completion (Only answer if completion status is not “Already Completed” or “Discontinued”).
  - o Anticipated completion date (Only answer if completion status is not “Already Completed” or “Discontinued”).
  - o What are your plans to redirect funds budgeted for this step to another step or a different intervention? (Only answer completion status is “Discontinued”)

o

## Technical Assistance

- Would technical assistance be helpful in the implementation of your interventions within this strategy?
  - o If yes, what type of support may be needed?

## List of Questions for Strategy 3 (Prevention): Stigma Reduction

### Data To Action

- Describe all data analyzed to inform interventions for this strategy and any partner involvement with analysis, interpretation, and program refinement (provide examples of relevant analysis).
- How did implementation of interventions change as a result of the use of these data?
- What were the impacts or results from the implementation change?
- What additional data gaps, if any, did you identify?
- Provide examples of how you used/shared near real-time data (e.g., ODMAP, syndromic) to inform rapid community responses to spikes in drug overdoses or dangerous drug supplies.
- Describe your approach to using data and implementing interventions to address the needs of persons at high risk of overdose.

## Intervention Progress

**For each intervention:**

- Describe your progress to date for this intervention, including progress engaging your priority populations. (Highlight any significant successes or challenges. Describe barriers and how you overcame them and any relevant facilitators.)
- Please list all relevant outputs and deliverables produced as a result of this intervention (select all that apply)
  - o Publications
  - o Presentations
  - o Abstracts
  - o Toolkits
  - o Dashboards/Data Viz
  - o Training Materials
  - o Other
- Please indicate whether you will continue with this intervention in the next year? (*whether this is continued or not should be reflected in the workplan for the coming year*)

## Step-Level Progress

- Indicate your completion status for this step. (*Already Completed, On Schedule, Delayed, Discontinued*)
  - o Why was this step not completed (Only answer if completion status is not “Already Completed” or “On Schedule”).
  - o What are your plans for completion (Only answer if completion status is not “Already Completed” or “Discontinued”).
  - o Anticipated completion date (Only answer if completion status is not “Already Completed” or “Discontinued”).
  - o What are your plans to redirect funds budgeted for this step to another step or a different intervention? (Only answer completion status is “Discontinued”)

o

## Technical Assistance

- Would technical assistance be helpful in the implementation of your interventions within this strategy?
  - o If yes, what type of support may be needed?

## List of Questions for Strategy 4 (Prevention): Clinician and Health Systems Best Practices

### Data To Action

- Describe all data analyzed to inform interventions for this strategy and any partner involvement with analysis, interpretation, and program refinement (provide examples of relevant analysis).
- How did implementation of interventions change as a result of the use of these data?
- What were the impacts or results from the implementation change?

- What additional data gaps, if any, did you identify?
- Provide examples of how you used/shared near real-time data (e.g., ODMAP, syndromic) to inform rapid community responses to spikes in drug overdoses or dangerous drug supplies.
- Describe your approach to using data and implementing interventions to address the needs of persons at high risk of overdose.

## Intervention Progress

### For each intervention:

- Describe your progress to date for this intervention, including progress engaging your priority populations. (Highlight any significant successes or challenges. Describe barriers and how you overcame them and any relevant facilitators.)
- Please list all relevant outputs and deliverables produced as a result of this intervention (select all that apply)
  - o Publications
  - o Presentations
  - o Abstracts
  - o Toolkits
  - o Dashboards/Data Viz
  - o Training Materials
  - o Other
- Please indicate whether you will continue with this intervention in the next year? (*whether this is continued or not should be reflected in the workplan for the coming year*)

## Step-Level Progress

- Indicate your completion status for this step. (*Already Completed, On Schedule, Delayed, Discontinued*)
  - o Why was this step not completed (Only answer if completion status is not “Already Completed” or “On Schedule”).
  - o What are your plans for completion (Only answer if completion status is not “Already Completed” or “Discontinued”).
  - o Anticipated completion date (Only answer if completion status is not “Already Completed” or “Discontinued”).
  - o What are your plans to redirect funds budgeted for this step to another step or a different intervention? (Only answer completion status is “Discontinued”)

o

## Technical Assistance

- Would technical assistance be helpful in the implementation of your interventions within this strategy?
  - o If yes, what type of support may be needed?

## List of Questions for Strategy 5 (Prevention): Health IT Enhancements

### Data To Action

- Describe all data analyzed to inform interventions for this strategy and any partner involvement with analysis, interpretation, and program refinement (provide examples of relevant analysis).
- How did implementation of interventions change as a result of the use of these data?
- What were the impacts or results from the implementation change?
- What additional data gaps, if any, did you identify?
- Provide examples of how you used/shared near real-time data (e.g., ODMAP, syndromic) to inform rapid community responses to spikes in drug overdoses or dangerous drug supplies.
- Describe your approach to using data and implementing interventions to address the needs of persons at high risk of overdose.

### Intervention Progress

#### For each intervention:

- Describe your progress to date for this intervention, including progress engaging your priority populations. (Highlight any significant successes or challenges. Describe barriers and how you overcame them and any relevant facilitators.)
- Please list all relevant outputs and deliverables produced as a result of this intervention (select all that apply)
  - o Publications
  - o Presentations
  - o Abstracts
  - o Toolkits
  - o Dashboards/Data Viz
  - o Training Materials
  - o Other
- Please indicate whether you will continue with this intervention in the next year? (*whether this is continued or not should be reflected in the workplan for the coming year*)

### Step-Level Progress

- Indicate your completion status for this step. (*Already Completed, On Schedule, Delayed, Discontinued*)
  - o Why was this step not completed (Only answer if completion status is not “Already Completed” or “On Schedule”).

- o What are your plans for completion (Only answer if completion status is not “Already Completed” or “Discontinued”).
- o Anticipated completion date (Only answer if completion status is not “Already Completed” or “Discontinued”).
- o What are your plans to redirect funds budgeted for this step to another step or a different intervention? (Only answer completion status is “Discontinued”)

o

## Technical Assistance

- Would technical assistance be helpful in the implementation of your interventions within this strategy?
  - o If yes, what type of support may be needed?

## List of Outcome-level Questions across Prevention Strategies

### Outcome Reporting

- How have individuals from priority populations and people with lived experience been engaged in the evaluation of the interventions within this strategy (e.g., needs assessment, planning for evaluation, interpreting evaluation findings, implications for program improvement)?
- Share a successful example of how you have shared your evaluation findings with partners.
- Share one or more example(s) of how you have used your evaluation findings to inform program improvements

### Outcome-Specific Questions

- Describe your progress toward achieving the outcome through your interventions in this strategy:
- Provide the evaluation questions you are addressing for this outcome:
- Present and define the indicators you are measuring:
- Identify the data sources you are using to evaluate this outcome:
- Describe your qualitative and/or quantitative data analyses:
- Describe your evaluation findings:

## List of Prevention Strategy Budget Questions

- Recipients should provide estimates as an approximate percentage of the total award that will be obligated towards the interventions listed.
  - o Funding for navigator interventions
  - o Other linkage to and retention in care interventions
  - o Funding for naloxone distribution interventions
  - o Other harm reduction interventions
  - o Stigma reduction interventions
  - o Advancing guideline concordant care
  - o Other clinician and health systems best practices interventions
  - o Health IT enhancement interventions

## List of Success Stories Questions: Surveillance

**SURVEILLANCE STRATEGIES:** Please answer the following question with consideration of all of your surveillance strategies.

### SUCCESS STORIES

Success stories are particularly important tools that: Allow CDC to elevate the work of jurisdictions, foster connections and sharing of promising practices among jurisdictions, and inform areas/ideas where TA could be introduced/enhanced.

**Title (Let your readers know what to expect from the story)**

#### Challenge

- Describe the public health problem that you sought to address.
- Provide the data sources that were used to identify the problem and the priority population.

#### Approach

- Describe the priority population.
- How were the data used?
- WHERE and WHEN did the intervention take place?
- HOW did the intervention address the Challenge?
- WHO was involved, including major partners?

#### Results

- What happened as a result of the work you did?
- Why is that result important? (Describe the “so what?”)

## List of Strategy 6 (Surveillance): Surveillance Infrastructure Building

For each objective proposed in the workplan (prepopulated from the workplan):

- Describe progress on the objective proposed in workplan, including accomplishments and barriers.
- List major outputs produced (e.g., data cube created, staff hired, or analyses/data products disseminated), including providing web links to data products when available.

## Component B

### List of Questions for Component B (Surveillance): Drug Product and Paraphernalia Testing

#### *Implement Surveillance System*

- Identify all laboratory(ies) performing testing.
- For each laboratory identified, provide the following information:
  - o Confirm all specimens were tested for drugs required by CDC. If not, why.

- o If laboratory(ies) used for testing were changed during the funding year, please explain the changes and why the change was made.
- Report total drug product and paraphernalia specimens tested during the funding year (in Year 1, the recipient may report 0; during Year 2 – Year 5, the recipient must describe how they are working to increase the number of samples testing if they tested < 500 samples per year.)
- Describe the types of samples that have been tested during the reporting period (*select all that apply*):
  - o Drug product samples (e.g., pills, powders)
  - o Syringes
  - o Plastic bags containing drugs
  - o Cooker
  - o Cotton
  - o Foil
  - o Other drug paraphernalia
  - o Other (provide text)
- Briefly describe where and how the samples were collected. This should include a description of:
  - o How the samples were obtained (e.g., ME/C, law enforcement)?
  - o The number of different agencies or sites that provided samples (e.g., multiple ME/Cs compared to a single ME/C).
  - o Whether all samples or a subset of samples were tested. If a subset were tested, please briefly describe the sampling plan.
  - o Describe any major challenges with sample collection, including how you addressed or are addressing these challenges.
- Do you receive the additional ME/C funding under Component B?
  - o If YES, please describe key enhancements to ME/C drug overdose death investigations and/or sharing of data between ME/C agencies and your local health department

## CDC Data Reporting and Workgroup Participation Requirements

- Report whether you submitted test findings to CDC on time during the reporting period.
  - o If NO, please describe the actions you are taking to report the testing data on-time in the future.
- Report whether CDC certified testing results were submitted to CDC for public reporting during the funding year.
  - o If test results were not certified for public reporting during Year 2 – Year 5, describe how you are addressing data collection or quality issues identified by CDC.
- Report the number of workgroup meetings attended during the fiscal year.
  - o If you missed 2 or more meetings, please describe why and how this will be prevented in the future.

## Disseminate Data

- Describe progress towards disseminating data products and identify key accomplishments and barriers.
  - o List data products, using bullet points, released during the funding year including reports, alerts, and key presentations. Web links should be included if available.

## Technical Assistance

- Would technical assistance be helpful in the implementation of your surveillance objectives within this strategy?
  - o If YES, what type of support may be needed?

## Component C

### List of Questions for Component C (Surveillance): Linkage to and Retention in Care Surveillance

#### Implement Surveillance System

- Select the entry point(s) for which your jurisdiction collected linkage to and retention to care surveillance indicators during the reporting period (*select all that apply*)
  - o Emergency department
  - o Other hospital department
  - o Emergency medical services (EMS)
  - o Community partners
  - o Public safety partners
  - o Other (provide text)
- Describe the data sources that your jurisdiction used to support linkage to and retention in care surveillance during the reporting period.
- Describe progress made in obtaining and/or maintaining access to key data sources to support linkage to and retention in care surveillance during the reporting period, including key challenges and strategies used to address these challenges.
- Describe progress made in establishing or maintaining data systems to support linkage to and retention in care surveillance during the reporting period, including key challenges and strategies used to address these challenges.

#### CDC Data Reporting and Workgroup Participation Requirements

- Were all required linkage to and retention in care surveillance indicators submitted to CDC on time during the reporting period?
- Were any optional linkage to and retention in care surveillance indicators submitted to CDC during the reporting period?
- Were all requirements met, as outlined in the linkage to and retention in care surveillance technical guidance?
  - o If NO, describe the barriers to meeting these requirements and how you plan to address them.
- Report the number of workgroup meetings attended during the reporting period.
  - o If you missed 2 or more meetings, please describe why and how this will be prevented in the future.

#### Disseminate Data

- Did you develop at least one data product using linkage to and retention in care surveillance data during the reporting period?
  - o If NO, describe the barriers and how you plan to address them.
- Were any of these data products shared with key local partners and/or the public to support drug overdose response and prevention efforts in your jurisdiction during the reporting period?
  - o If NO, describe why and how you plan to improve dissemination in the future.
  - o If YES, how were the data products disseminated and used to guide prevention activities?
- Please provide a list of relevant data products that were produced and disseminated using data from this activity, including key details and links to products where possible.

## **Technical Assistance**

- Would technical assistance be helpful in the implementation of your surveillance objectives within this strategy?
  - o If yes, what type of support may be needed?